



20th KM Hosur Road, Electronics City, Bangalore 560 100

Bangalore, July 13, 2016

Biocon's Q1 FY 2016-17 Results Conference Call

At 9.00 am IST on July 22, 2016

Biocon Limited (BSE code: 532523, NSE Id: BIOCON) will announce results for the first quarter of fiscal 2016-17, ended June 30, 2016 on July 21, 2016. Following the announcement, the management of Biocon Limited will host an earnings call to discuss the Company's financial performance on July 22, 2016 at 9.00 am IST.

Details of the conference call are as under:

Date:	Friday, July 22, 2016
Time:	9.00 am IST
Add to your Calendar	
Dial-in Numbers:	
Primary Number	+91 22 3938 1081
Secondary Number	+91 22 6746 5891
Local Access Number	6000 1221 (Ahmedabad, Bangalore, Bhubaneswar, Chandigarh, Chennai, Coimbatore, Delhi, Goa, Guntur, Gurgaon, Hyderabad, Indore, Jamshedpur, Kanpur, Kochi/Cochin, Kolhapur, Kolkata, Nagpur, Noida, Patna, Pune, Raipur, Rajkot, Surat, Trivandrum, Vadodara, Vijayawada. Accessible from all major carriers except BSNL/MTNL.) 3940 3977 (Available in - Ahmedabad, Bangalore, Chandigarh, Chennai, Gurgaon (NCR), Hyderabad, Kochi/Cochin, Kolkata, Lucknow, Pune. Accessible from all carriers)
International Toll Numbers	USA: +1 323 386 8721 UK: +44 20 3478 5524 Singapore: +65 3157 5746 Hong Kong: +852 3018 6877
Pre-Registration Facility (Special Facility where you can pre-register for the call, and then directly dial-in on the day of the call, without waiting for the operator. You will also get reminders to attend the investor call.)	<ul style="list-style-type: none">• Step 1: Pre-register here. You will receive a passcode and a pin for the call on the registered email address• Step 2: Dial into the call on the Conference Call date, enter the passcode & pin as prompted.• Step 3: You are directly connected to the call
As participation in the call is limited, early registration is encouraged. The operator will provide instructions on asking questions before and during the call.	

Replay Facility	The replay will be available after the earnings call ends. Replay available till July 29, 2016. Dial in number: +91 22 3065 2322/ 6181 3322 Playback ID: 44711
Transcript	Will be made available after a few days on the Company's website: www.biocon.com

About Biocon

Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is India's largest and fully-integrated, innovation-led biopharmaceutical company. As an emerging global biopharmaceutical enterprise serving customers in over 100 countries, it is committed to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through innovative products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. It has successfully developed and taken a range of Novel Biologics, Biosimilars, differentiated Small Molecules and affordable Recombinant Human Insulin and Analogs from 'Lab to Market'. Some of its key brands are INSUGEN® (rh-insulin), BASALOG® (Glargine), CANMAb™ (Trastuzumab), BIOMAb-EGFR™ (Nimotuzumab) and ALZUMAb™ (Itolizumab), a 'first in class' anti-CD6 monoclonal antibody. It has a rich pipeline of Biosimilars and Novel Biologics at various stages of development including Insulin Tregopil, a high potential oral insulin analog. For more details, visit: www.biocon.com

Contact:

For further information please contact:

Saurabh Paliwal

Investor Relations – Biocon Limited

☎ +91 80 6775 2040

✉: saurabh.paliwal@biocon.com

Diwakar Pingle

Christensen Investor Relations

☎: +91 22 4215 0210

✉: dpingle@ChristensenIR.com

Safe Harbor: *Certain of the statements that may be made or discussed at the conference call may be forward-looking statements and/or based on management's current expectations and beliefs concerning future developments and their potential effects upon Biocon and its subsidiaries/ associates. There can be no assurance that future developments affecting Biocon and its subsidiaries / associates will be those anticipated by management. These forward-looking statements are not a guarantee of future performance and involve risks and uncertainties and there are important factors that could cause actual results to differ, possibly materially, from expectations reflected in such forward-looking statements. Biocon does not intend, and is under no obligation, to update any particular forward-looking statement made at the conference call.*